MarketInOut Stock Screener Log In | Sign Up

AnaptysBio Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 11/20/2026
AnaptysBio Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,364.6 mln
Float27.92 mln
Earnings Date03/09/2027

EPS

6.52
Strong

P / E

7.15
Undervalued

Piotroski F-Score

5 / 9
Neutral

Beneish M-Score

5.34
Highly suspicious

Relative Strength

90 / 100
Top performer

Debt / Equity

12.60
Extremely leveraged

Business Description

AnaptysBio Inc. is a San Diego-based biotechnology company working to develop treatments for autoimmune and inflammatory conditions. Its pipeline includes several promising drug candidates at various stages of clinical testing, targeting diseases such as rheumatoid arthritis, psoriasis, celiac disease, and certain cancers. The company works alongside partners GSK and Vanda to advance its research programs from early discovery through clinical development.

Key Fundamentals

EPS6.52
P/E7.15
ROE1,776
RPS2.04
ROIC142
ROA54.25
Interest Cover1.50
EBITDA, mln130
EV / EBITDA11.51
EV / EBIT11.70
Revenue, mln192
EV / Revenue7.79

Quote Details

Last 46.63
Change -0.77 (-1.62%)
Open 47.49
Volume 431,388
Turnover 20,115,622
Average Volume 386,658

Financial Ratios

Pre-Tax Profit Margin25
Leverage Ratio14.75
Current Ratio8.40
Price / Book77.86
Price / Tangible Book78.39
Price / Cash Flow38.21
Price / Free Cash Flow43.84
Debt / Equity12.60
Price / Sales7.54

Financial Strength

Altman Z-Score2.63
Piotroski F-Score 5 / 9
Beneish M-Score5.34
Price to Graham Number5.15
Short Ratio9.38
Short % of Float37.03

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 0.82% 92 / 100   
1 Month -3.06% 68 / 100   
2 Months -21.88% 35 / 100   
6 Months -21.91% 34 / 100   
1 Year 89.01% 97 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog